Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (KHTRF)
:KHTRF
Total Valuation
Knight Therapeutics has a market cap or net worth of $443.85M. The enterprise value is $441.39M.
Market Cap$443.85M
Enterprise Value$441.39M
Share Statistics
Knight Therapeutics has 99,448,490 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99,448,490
Owned by Insiders30.46%
Owned by Institutions0.09%
Financial Efficiency
Knight Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee440.54K
Profits Per Employee-22.60K
Employee Count745
Asset Turnover0.35
Inventory Turnover1.91
Valuation Ratios
The current PE Ratio of Knight Therapeutics is -33.13. Knight Therapeutics’s PEG ratio is 0.86.
PE Ratio-33.13
PS Ratio0.00
PB Ratio0.75
Price to Fair Value0.75
Price to FCF21.47
Price to Operating Cash Flow15.52
PEG Ratio0.86
Income Statement
In the last 12 months, Knight Therapeutics had revenue of 328.20M and earned -16.84M in profits. Earnings per share was -0.16.
Revenue328.20M
Gross Profit152.65M
Operating Income-2.89M
Pretax Income-21.99M
Net Income-16.84M
EBITDA40.90M
Earnings Per Share (EPS)-0.16
Cash Flow
In the last 12 months, operating cash flow was 43.06M and capital expenditures -32.18M, giving a free cash flow of 11.98M billion.
Operating Cash Flow43.06M
Free Cash Flow11.98M
Free Cash Flow per Share0.12
Dividends & Yields
Knight Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.15
52-Week Price Change3.24%
50-Day Moving Average4.13
200-Day Moving Average4.03
Relative Strength Index (RSI)67.27
Average Volume (3m)2.90K
Important Dates
Knight Therapeutics upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Knight Therapeutics as a current ratio of 3.20, with Debt / Equity ratio of 7.52%
Current Ratio3.20
Quick Ratio2.40
Debt to Market Cap0.11
Net Debt to EBITDA―
Interest Coverage Ratio-0.23
Taxes
In the past 12 months, Knight Therapeutics has paid -5.15M in taxes.
Income Tax-5.15M
Effective Tax Rate0.23
Enterprise Valuation
Knight Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Knight Therapeutics has $172.32M in cash and marketable securities with C$0.00 in debt, giving a net cash position of -$114.10M billion.
Cash & Marketable Securities$172.32M
Total DebtC$0.00
Net Cash-$114.10M
Net Cash Per Share-$1.15
Tangible Book Value Per Share$3.51
Margins
Gross margin is 38.61%, with operating margin of -0.88%, and net profit margin of -5.13%.
Gross Margin38.61%
Operating Margin-0.88%
Pretax Margin-6.70%
Net Profit Margin-5.13%
EBITDA Margin12.46%
EBIT Margin-2.89%
Analyst Forecast
The average price target for Knight Therapeutics is $5.72, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.72
Price Target Upside28.25% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―